Author

V. Nangia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Assay:DNA methylation· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. Abbasi· 1 shared A. Langenbucher· 1 shared A. N. Hata· 1 shared A. Riley· 1 shared A. T. Shaw· 1 shared C. Benes· 1 shared C. Chan· 1 shared C. J. Ott· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Abbasi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Multiple cancer types rapidly escape from multiple MAPK inhibitors to generate mutagenesis-prone subpopulations

T. E. Hoffman, C. Yang, V. Nangia, C. R. Ill, S. L. Spencer

The paper shows that multiple cancer types rapidly escape MAPK inhibitors by forming mutagenesis-prone subpopulations through ATR and FA pathway dependencies.

bioRxiv · Mar 17, 2023Cancer Biology

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

H. Isozaki, A. Abbasi, N. Nikpour, A. Langenbucher, W. Su, M. Stanzione, H. Frisco-Cabanos, F. M. Siddiqui, N. Phan, P. Jalili, S. Oh, D. Timonina, S. Bilton, M. Gomez-Caraballo, H. L. Archibald, , A. N. Hata

This study shows that APOBEC3A mutagenesis driven by targeted therapies promotes drug resistance in non-small cell lung cancer.

bioRxiv · Jan 20, 2021Cancer Biology